EPO and diabetic kidney disease: A previous study indicated that older age, high body mass index, pretreatment for Hb, use of angiotensin conversion enzyme/angiotensin receptor blocker, and diabetic nephropathy were associated with increased erythropoietin requirements in anemic p-CKDs [21].